NAFDAC Drug Evaluation & Research (DER) Directorate Guidelines for Clinical Investigation of Medicinal Products in Paediatric Population
Ministry of Health, National Agency for Food and Drug Administration and Control, Nigeria
The guideline has an overall objective to encourage and facilitate timely paediatric medicinal product development in Nigeria. It provides an outline of critical issues in paediatric drug development and the approaches to the safe, efficient and ethical study of medicinal products in the paediatric population.
You are viewing a previous version. Click here to view the current version.
Read in full screenProcess Flow
Department of Drug Evaluation and Research ⬤
Office of the Director General NAFDAC ⬤
Office of the Permanent Secretary, Ministry of Health ⬤
Office of the Minister of State for Health ⬤
Office of the minister for health ⬤
Federal Executive Council ⬤
NAFDAC Drug Evaluation & Research (DER) Directorate Guidelines for Clinical Investigation of Medicinal Products in Paediatric Population Current Version
January 2022
The guideline has an overall objective to encourage and facilitate timely paediatric medicinal product development in Nigeria. It provides an outline of critical issues in paediatric drug development and the approaches to the safe, efficient and ethical study of medicinal products in the paediatric population.
Thank you for requesting an expert analysis
A member of our team will review your request and reply back to the email address on file.